Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis

World Journal of Gastroenterology

Volumn 19, Issue 40, 2013, Pages 6911-6918

  Ma, Yan Yan ^a   Li, Lin ^a   Yu, Chao Hui ^a   Shen, Zhe ^a   Chen, Li Hua ^a   Li, You Ming ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Insulin resistance; Liver function; Meta analysis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Probiotics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; PREBIOTIC AGENT; TUMOR NECROSIS FACTOR;

ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; INSULIN RESISTANCE; INTESTINE FLORA; META ANALYSIS; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL (TOPIC);

INSULIN RESISTANCE; LIVER FUNCTION; META-ANALYSIS; NONALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS; PROBIOTICS;

CHI-SQUARE DISTRIBUTION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; INTESTINES; LIPID METABOLISM; LIVER; ODDS RATIO; PROBIOTICS; TREATMENT OUTCOME;

EID: 84886999533     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i40.6911     Document Type: Article

References (60)

1. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22: 1129-1133 [PMID: 16108837 DOI: 10.1111/j.1464-5491.2005.01748.x]
2. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894 [PMID: 11567710 DOI: 10.1016/ S0140-6736(01)06042-1]
3. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-544 [PMID: 14987322 DOI: 10.1111/j.1365-2036.2004.01888.x]
4. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-196 [PMID: 14752837 DOI: 10.1002/ hep.20012]
5. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384 [PMID: 10453959]
6. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004; 174: 193-196 [PMID: 15135271 DOI: 10.1016/j.atherosclerosis.2004.01.008]
7. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48: 119-128 [PMID: 18537181 DOI: 10.1002/ hep.22336]
8. Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2003; 18: 1220-1221 [PMID: 12974918 DOI: 10.1046/j.1440-1746.2003.03156.x]
9. Georgescu EF, Georgescu M. Therapeutic options in nonalcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16: 39-46 [PMID: 17410287]
10. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, Cheng CL, Wee A, Lim SG. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008; 2: 196-201 [PMID: 19669304 DOI: 10.1007/s12072-008-9058-1]
11. Rinella ME, Koppe S, Brunt EM, Elias M, Gottstein J, Green RM. Pentoxifylline improves ALT and histology in patients with NASH: a double-blind placebo controlled trial. Gastroenterology 2009; 136 Suppl 1: 88-89 [DOI: 10.1016/S0016-5085(09)60398-X]
12. Salminen S. Uniqueness of probiotic strains. IDF Nutr Newsletter 1996; 5: 16-18
13. Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad Med J 2004; 80: 516-526 [PMID: 15356352 DOI: 10.1136/pgmj.2003.008664]
14. Lilly DM, Stillwell RH. Probiotics: Growth-Promoting Factors Produced by Microorganisms. Science 1965; 147: 747-748 [PMID: 14242024 DOI: 10.1126/science.147.3659.747]
15. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638 [PMID: 15831718 DOI: 10.1126/science.1110591]
16. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-1359 [PMID: 16741115 DOI: 10.1126/science.1124234]
17. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887 [PMID: 19291785 DOI: 10.1002/hep.22848]
18. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-543 [PMID: 15942443 DOI: 10.1097/01.mcg.0000165671.25272.0f]
19. Macfarlane GT, Cummings JH. Probiotics, infection and immunity. Curr Opin Infect Dis 2002; 15: 501-506 [PMID: 12686883]
20. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-591 [PMID: 11522742 DOI: 10.1053/gast.2001.27224]
21. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519 [PMID: 12583961 DOI: 10.1016/ S0140-6736(03)12489-0]
22. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15: 1090-1095 [PMID: 22013734]
23. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011; 52: 740-743 [PMID: 21505361 DOI: 10.1097/MPG.0b013e31821f9b85]
24. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructooligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545-553 [PMID: 21901256 DOI: 10.1007/s10620-011-1887-4]
25. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013; 12: 256-262 [PMID: 23396737]
26. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 Suppl 1: S5-10 [PMID: 16540768 DOI: 10.1097/01.mcg.0000168638.84840.ff]
27. Rodríguez-Hernández H, Cervantes-Huerta M, Rodríguez-Moran M, Guerrero-Romero F. Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. A nn Hepatol 2011; 10: 486-492 [PMID: 21911890]
28. Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40 Suppl 1: S39-S43 [PMID: 16540766 DOI: 10.1097/01.mcg.0000168641.31321.fa]
29. Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009; 48: 587-596 [PMID: 19412008 DOI: 10.1097/MPG.0b013e31818e04d1]
30. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885-904 [PMID: 22278337 DOI: 10.1007/ s00125-011-2446-4]
31. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-211 [PMID: 11156641 DOI: 10.1136/gut.48.2.206]
32. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031 [PMID: 17183312 DOI: 10.1038/nature05414]
33. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023 [PMID: 17183309 DOI: 10.1038/4441022a]
34. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009; 106: 2365-2370 [PMID: 19164560 DOI: 10.1073/pnas.0812600106]
35. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, Martines D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G518-G525 [PMID: 17023554 DOI: 10.1152/ajpgi. 00024.2006]
36. Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis 2010; 28: 737-744 [PMID: 21525758 DOI: 10.1159/000324281]
37. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumenliver interactions and possible role for probiotics. J Hepatol 2003; 38: 681-687 [PMID: 12713883]
38. Kaplowitz N. Mechanisms of liver cell injury. J Hepatol 2000; 32: 39-47 [PMID: 10728793 DOI: 10.1016/S0168-8278(00)80414-6]
39. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185 [PMID: 22297845 DOI: 10.1038/nature10809]
40. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]
41. Montecucco F, Mach F. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? Endocr Metab Immune Disord Drug Targets 2008; 8: 301-307 [PMID: 19075784 DOI: 10.2174/187153008786848268]
42. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415 [PMID: 7738205 DOI: 10.1172/JCI117936]
43. Pinto Lde F, Compri CM, Fornari JV, Bartchewsky W, Cintra DE, Trevisan M, Carvalho Pde O, Ribeiro ML, Velloso LA, Saad MJ, Pedrazzoli J, Gambero A. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice. Liver Int 2010; 30: 603-610 [PMID: 20088867 DOI: 10.1111/j.1478-3231.2009.02200.x]
44. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410 [PMID: 10902785 DOI: 10.1210/jc.85.7.2402]
45. Aguilera E, Recasens M, Flores L, Ricart MJ, Casamitjana R, Fernández-Cruz L, Esmatjes E. HOMA test in diabetic patients with simultaneous pancreas and kidney transplantation. Transplant Proc 2002; 34: 206-208 [PMID: 11959249 DOI: 10.1016/S0041-1345(01)02831-7]
46. Gilliland SE, Walker DK. Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce a hypocholesterolemic effect in humans. J Dairy Sci 1990; 73: 905-911 [PMID:2111831 DOI: 10.3168/jds. S0022-0302(90)78747-4]
47. De Rodas BZ, Gilliland SE, Maxwell CV. Hypocholesterolemic action of Lactobacillus acidophilus ATCC 43121 and calcium in swine with hypercholesterolemia induced by diet. J Dairy Sci 1996; 79: 2121-2128 [PMID: 9029351 DOI: 10.3168/jds.S0022-0302(96)76586-4]
48. Usman A. Effect of administration of Lactobacillus gasseri on serum lipids and fecal steroids in hypercholesterolemic rats. J Dairy Sci 2000; 83: 1705-1711 [PMID: 10984145 DOI: 10.3168/jds.S0022-0302(00)75039-9]
49. Pereira DI, Gibson GR. Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. Crit Rev Biochem Mol Biol 2002; 37: 259-281 [PMID: 12236466 DOI: 10.1080/10409230290771519]
50. Ibnou-Zekri N, Blum S, Schiffrin EJ, von der Weid T. Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro. Infect Immun 2003; 71: 428-436 [PMID: 12496193 DOI: 10.1128/IAI.71.1.428-436.2003]
51. Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol 1994; 77: 412-420 [PMID: 7989269 DOI: 10.1111/j.1365-2672.1994.tb03443.x]
52. McCartney AL, Wenzhi W, Tannock GW. Molecular analysis of the composition of the bifidobacterial and lactobacillus microflora of humans. Appl Environ Microbiol 1996; 62: 4608-4613 [PMID: 8953730]
53. Malasanos TH, Stacpoole PW. Biological effects of omega-3 fatty acids in diabetes mellitus. Diabetes Care 1991; 14: 1160-1179 [PMID: 1773702 DOI: 10.1136/gut.52.7.988]
54. Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, Pennisi G, Li Volti G, Galvano F. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010; 22: 199-206 [PMID: 19730107 DOI: 10.1097/MEG.0b013e328330a8d3]
55. Vanni E, Bugianesi E. The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance? Hepatology 2009; 49: 1790-1792 [PMID: 19475679 DOI: 10.1002/hep.23036]
56. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-1412 [PMID: 7782892]
57. Tannock GW, Wilson CM, Loach D, Cook GM, Eason J, O' Toole PW, Holtrop G, Lawley B. Resource partitioning in relation to cohabitation of Lactobacillus species in the mouse forestomach. ISME J 2012; 6: 927-938 [PMID: 22094343 DOI: 10.1038/ismej.2011.161]
58. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 1995; 108: 975-982 [PMID: 7698613 DOI: 10.1016/0016-5085(95)90192-2]
59. Hofacre CL, Mathis GF, Quiroz MA. Natural alternatives to prevent necrotic enteritis. Int Poult Prod 2005; 13: 7-9
60. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. Selective increases of bifidobacteria in gut microflora improve high-fat-dietinduced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374-2383 [PMID: 17823788 DOI: 10.1007/s00125-007-0791-0]